PARADIGM-HF衍生并在ATMOSPHERE和SwedeHF验证的慢性心衰死亡与发病预测模型
本研究基于PARADIGM-HF试验8399例患者(8011例有完整基线数据)开发心衰预后模型,采用多变量逐步分析和Harrell C统计量评估区分度,并在ATMOSPHERE研究和瑞典心衰注册库中外部验证。模型对1年和2年心血管死亡、全因死亡及心血管死亡或心衰住院复合终点具有良好区分能力,NT-proBNP是最强独立预测因子,并提供了在线计算器。
要点
- 模型在PARADIGM-HF开发,1年复合终点C统计量0.74(95%CI 0.71-0.76),2年0.71(95%CI 0.70-0.73)。
- 外部验证ATMOSPHERE中1年复合终点C统计量0.71(95%CI 0.69-0.72),2年0.70(95%CI 0.68-0.71)。
- NT-proBNP按χ2排序是各结局最强独立预测因子。
核心结论
- 预测模型表现良好,并在地理代表性广泛、接受当代循证治疗的大规模心衰队列中完成开发和外部验证。
研究设计与样本
- 多变量逐步分析,使用Harrell C统计量评估区分度;衍生队列为PARADIGM-HF试验8399例参与者,完整基线临床数据8011例。
- 模型在ATMOSPHERE研究和瑞典心衰注册库(SwedeHF)中验证;数据分析时间为2016年6月至2018年6月。
主要发现
- PARADIGM-HF参与者平均(SD)年龄64(11.4)岁,男性78.2%(6567/8399),NYHA II级70.6%(5919/8399)。
- 平均随访27个月期间,1546例死亡,2031例发生心血管死亡或心衰住院。
- 共同变量包括男性、种族/族裔(黑人或亚洲人)、地区(中欧或拉丁美洲)、心衰病程超过5年、NYHA III/IV级、左室射血分数、糖尿病、基线β受体阻滞剂使用和沙库巴曲/缬沙坦分配。
- 按χ2排序,NT-proBNP是各结局最强独立预测因子。
- PARADIGM-HF中1年和2年C统计量:主要复合终点0.74(95%CI 0.71-0.76)和0.71(95%CI 0.70-0.73),心血管死亡0.73(95%CI 0.71-0.75)和0.71(95%CI 0.69-0.73),全因死亡0.71(95%CI 0.69-0.74)和0.70(95%CI 0.67-0.74)。
临床怎么用
- 模型可用于计算慢性心衰患者1年和2年死亡或住院风险,在线计算器网址为http://www.predict-hf.com。
- 预测风险有助于医生讨论疾病修饰治疗、高级治疗或临终关怀的适宜性和时机。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Accurate prediction of risk of death or hospitalizations in patients with heart failure (HF) may allow physicians to explore how more accurate decisions regarding appropriateness and timing of disease-modifying treatments, advanced therapies, or the need for end-of-life care can be made. OBJECTIVE: To develop and validate a prognostic model for patients with HF. DESIGN, SETTING, AND PARTICIPANTS: Multivariable analyses were performed in a stepwise fashion. Harrell C statistic was used to assess the discriminative ability. The derivation cohort was Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM-HF) participants. The models were validated using the Aliskiren Trial to Minimize Outcomes in Patients with Heart Failure Trial (ATMOSPHERE) study and in the Swedish Heart Failure Registry (SwedeHF). A total of 8399 participants enrolled in PARADIGM-HF. Data were analyzed between June 2016 and June 2018. MAIN OUTCOMES AND MEASURES: Cardiovascular death, all-cause mortality, and the composite of cardiovascular death or HF hospitalization at both 1 and 2 years. RESULTS: Complete baseline clinical data were available for 8011 patients in PARADIGM-HF. The mean (SD) age of participants was 64 (11.4) years, 78.2% were men (n = 6567 of 8399), and 70.6% were New York Heart Association class II (n = 5919 of 8399). During a mean follow-up of 27 months, 1546 patients died, and 2031 had a cardiovascular death or HF hospitalization. The common variables were: male sex, race/ethnicity (black or Asian), region (Central Europe or Latin America), HF duration of more than 5 years, New York Heart Association class III/ IV, left ventricular ejection fraction, diabetes mellitus, β-blocker use at baseline, and allocation to sacubitril/valsartan. Ranked by χ2, N-terminal pro brain natriuretic peptide was the single most powerful independent predictor of each outcome. The C statistic at 1 and 2 years was 0.74 (95% CI, 0.71-0.76) and 0.71 (95% CI, 0.70-0.73) for the primary composite end point, 0.73 (95% CI, 0.71-0.75) and 0.71 (95% CI, 0.69-0.73) for cardiovascular death, and 0.71 (95% CI, 0.69-0.74) and 0.70 (95% CI, 0.67-0.74) for all-cause death, respectively. When validated in ATMOSPHERE, the C statistic at 1 and 2 years was 0.71 (95% CI, 0.69-0.72) and 0.70 (95% CI, 0.68-0.71) for the primary composite end point, 0.71 (95% CI, 0.69-0.74) and 0.70 (95% CI, 0.69-0.72) for cardiovascular death, and 0.71 (95% CI, 0.69-0.74) and 0.70 (95% CI, 0.68-0.72) for all-cause death, respectively. An online calculator was created to allow calculation of an individual's risk (http://www.predict-hf.com). CONCLUSIONS AND RELEVANCE: Predictive models performed well and were developed and externally validated in large cohorts of geographically representative patients, comprehensively characterized with clinical and laboratory data including natriuretic peptides, who were receiving contemporary evidence-based treatment.
引用
- Simpson J, Jhund PS, Lund LH, et al. Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. JAMA Cardiol. 2020. PMID: 31995119. doi:10.1001/jamacardio.2019.5850
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。